Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer immunotherapy using local interleukin 2 administration.

J Bubeník1, M Indrová

  • 1Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Prague.

Immunology Letters
|December 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of 5-azacytidine and trichostatin A on dendritic cell maturation.

Journal of biological regulators and homeostatic agents·2012
Same author

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.

British journal of cancer·2011
Same author

Tumour inhibitory effects of plasmid DNA.

Oncology reports·2011
Same author

IL-2 and gene-therapy of cancer.

International journal of oncology·2011
Same author

Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer.

International journal of oncology·2011
Same author

Cytokine gene-modified vaccines for immunotherapy of cancer (review).

International journal of oncology·2011

Local administration of interleukin-2 (IL-2) can inhibit sarcoma growth in mice. Unpurified IL-2 preparations showed greater tumor inhibition than recombinant IL-2, suggesting other lymphokines contribute to immunotherapy effectiveness.

Area of Science:

  • Immunology
  • Cancer Research
  • Biotechnology

Background:

  • Peri-tumoural administration of interleukin-2 (IL-2) has shown potential in inhibiting tumor growth.
  • Recombinant IL-2 (RIL-2) is a purified form used in immunotherapy.
  • Unpurified lymphoid IL-2 preparations may contain other active components.

Purpose of the Study:

  • To compare the tumor-inhibitory effects of purified RIL-2 with unpurified IL-2 preparations.
  • To investigate the role of other lymphokines in IL-2 immunotherapy.
  • To determine if RIL-2 combined with RIL-1 enhances therapeutic effects.

Main Methods:

  • Administering RIL-2 and unpurified IL-2 preparations peri-tumorally in mice with methylcholanthrene-induced sarcomas.
  • Comparing the tumor growth inhibition rates between different IL-2 preparations.

Related Experiment Videos

  • Assessing the effect of adding recombinant IL-1 (RIL-1) to RIL-2 therapy.
  • Correlating in vivo tumor sensitivity to RIL-2 with in vitro sensitivity to killer spleen (LAK) cells.

    • Main Results:

    • Unpurified human and rat lymphoid IL-2 preparations demonstrated significantly greater tumor inhibition than highly purified RIL-2.
    • RIL-2 immunotherapy inhibited the growth of approximately 80% of methylcholanthrene-induced sarcomas.
    • Admixture of RIL-1 did not potentiate the immunotherapeutic effects of RIL-2.
    • A direct correlation was observed between in vivo tumor sensitivity to RIL-2 and in vitro susceptibility to RIL-2-activated LAK cells.

    Conclusions:

    • Other lymphokines present in unpurified IL-2 preparations likely contribute to the observed anti-tumor effects.
    • LAK cells are the effector mechanism responsible for the anti-tumor efficacy of local RIL-2 immunotherapy.
    • In vitro assessment of LAK cell-mediated cytolysis sensitivity can predict tumor response to local RIL-2 immunotherapy in vivo.